Dana-Farber Debuts 50 Clinical Studies on Pancreatic Cancer and AI Diagnostics at AACR 2026

Dana-Farber Institute reveals new pancreatic cancer treatments, AI diagnostic tools, and microbiome maps at the 2026 AACR Annual Meeting in San Diego.

By: AXL Media

Published: Apr 18, 2026, 10:55 AM EDT

Source: Information for this report was sourced from EurekAlert!

New Therapeutic Combinations for Aggressive Cancers

In a significant update to pancreatic cancer treatment, investigators from the Dana-Farber Cancer Institute have released findings from a phase 1/2 trial involving a novel RAS inhibitor. Pancreatic adenocarcinoma is notorious for its high prevalence of RAS mutations, which drive growth in over 90 percent of cases. The study utilized daraxonrasib, a multi-selective inhibitor, in combination with standard chemotherapy for newly diagnosed metastatic patients. According to the research team, 90 percent of the forty participants achieved disease control or a clinical response. These promising results have directly paved the way for a global phase 3 trial to further validate the combination's efficacy against current standards of care.

Mapping the Multi-Kingdom Tumor Microbiome

Beyond traditional genetics, researchers are now looking at the microscopic organisms that reside within tumors to understand cancer progression. Dr. Anders Dohlman and his colleagues conducted the largest pan-cancer microbiome analysis to date, examining over 16,000 whole genomes. The study identified specific communities of bacteria, fungi, and even parasites like Trichomonas within oral and colorectal cancers. This research suggests a correlation between high microbial loads and hypermutated tumors, providing a new map of the tumor-associated environment. By identifying beneficial bacteria like Akkermansia muciniphila in early-onset cases, the institute aims to uncover how these microorganisms influence a patient's immune response to the disease.

Repurposing Diabetes Medication for Myeloma Interception

The institute is also exploring preventative interventions for blood cancers using common, low-cost medications. A phase 2 study investigated whether metformin, a standard oral treatment for type 2 diabetes, could halt the progression of precursor stages of multiple myeloma. Patients with conditions like MGUS or smoldering multiple myeloma currently have few pre-cancerous treatment options. The pilot trial demonstrated that daily metformin use resulted in a median 3.2 percent decrease in protein concentrations, a key biomarker for cancer risk, whereas the placebo group saw an increase. While the sample size was small, the findings suggest that metabolic interventions could potentially intercept cancer before it becomes symptomatic....